LivaNova (NASDAQ:LIVN) Upgraded by Wolfe Research to “Outperform” Rating

LivaNova (NASDAQ:LIVN) was upgraded by equities researchers at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Tuesday, Marketbeat Ratings reports. The firm presently has a $60.00 price target on the stock. Wolfe Research’s price target would indicate a potential upside of 37.43% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus decreased their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 8th. Robert W. Baird lifted their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Barclays reduced their price objective on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research note on Thursday, May 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $59.29.

LivaNova Stock Performance

Shares of LIVN opened at $43.66 on Tuesday. The firm has a market cap of $2.38 billion, a P/E ratio of 103.95 and a beta of 0.84. LivaNova has a twelve month low of $32.48 and a twelve month high of $61.94. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm’s 50 day moving average price is $38.70 and its two-hundred day moving average price is $44.75.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Summit Investment Advisors Inc. increased its position in LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after purchasing an additional 289 shares during the period. Central Pacific Bank Trust Division raised its holdings in LivaNova by 7.0% during the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock worth $173,000 after purchasing an additional 290 shares during the last quarter. CWM LLC lifted its position in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares during the period. Finally, Xponance Inc. boosted its stake in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after purchasing an additional 445 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.